21 Years of Experience
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Zolopa, Infectious Disease Specialist in Stanford, CA?
Dr. Andrew Zolopa, MD is an Infectious Disease Specialist, who primarily practices in Stanford, CA with 1 additional practice location. He has been practicing for over 21 years and is board certified. Dr. Zolopa is fluent in English, and is currently seeing new patients. To book an appointment or to confirm insurance options, please call Dr. Zolopa’s office at (208) 089-1800.
Where did Dr. Zolopa go to medical school and complete their residency?
Is Dr. Zolopa board certified as an Infectious Disease Specialist?
Yes, Dr. Andrew Zolopa, MD is board certified by the American Board of Internal Medicine
What languages does Dr. Zolopa speak?
Dr. Zolopa and their clinical team can communicate with patients in the following languages:
English
What conditions does an Infectious Disease Specialist like Dr. Zolopa typically treat?
As an Infectious Disease Specialist, conditions treated by Dr. Andrew Zolopa may include:
Please contact Dr. Zolopa's office directly to confirm care for your specific condition, for more information, or to schedule a consultation.
What procedures does an Infectious Disease Specialist like Dr. Zolopa typically perform?
As an Infectious Disease Specialist, procedures performed by Dr. Andrew Zolopa may include:
- Epidemiology Consultation
- Epidemiology Follow Up
- HIV / AIDS Consultation
- HIV / AIDS Follow Up
- Human Papillomavirus (HPV) Vaccine
- Infection Follow Up
- Lumbar Puncture
- Pertussis Vaccine
Please contact Dr. Zolopa's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Zolopa accept my insurance?
Please contact Dr. Zolopa's office to confirm accepted insurance plans.
Where is Dr. Zolopa's office located?
Recognitions
Publications
Low Baseline CD4+ Count Is Associated With Greater Bone Mineral Density Loss After Antiretroviral
, 2013
A Randomized Double-Blind Comparison of Coformulated
, 2013
Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS
, 2013
Patient monitoring and follow-up in lentiviral clinical trials
, 2013
Elevated Interleukin 8 and T-Helper 1 and T
, 2012
When to start ART in the setting of acute AIDS-related opportunistic infections: the time is now!
, 2012
Co-formulated elvitegravir
, 2012
Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase
, 2012
Association of Low Level Viremia with Inflammation and Mortality in HIV-Infected Adults
, 2011
Blood (1 -> 3)-beta-D-Glucan as a Diagnostic Test for HIV-Related Pneumocystis jirovecii Pneumonia
, 2011
Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment
, 2011
Inflammation and Mortality in HIV-Infected Adults: Alysis of the FRAM Study Cohort
, 2010
Concerns Regarding a R
, 2010
HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance
, 2010
Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections
, 2010
Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance
, 2010
Risk Factor Alyses for Immune Reconstitution Inflammatory Syndrome in a R
, 2010
Predicting Tipravir and Daruvir Resistance Using Genotypic, Phenotypic
, 2010
Intertiol Cohort Alysis of the Antiviral Activities of Zidovudine
, 2010
Activity of Elvitegravir, a Once-Daily Integrase Inhibitor
, 2010
Development of a didanosene genotypic resistance interpretation system based on large derivation
, 2010
Association of HIV Infection
, 2010
The evolution of HIV treatment guidelines: Current state-of-the-art of ART
, 2010
Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients
, 2009
Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease
, 2009
The use of resistance testing in the magement of HIV-1-infected patients
, 2009
Early Antiretroviral Therapy Reduces AIDS Progression
, 2009
Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS
, 2009
Maintaining Reduced Viral Fitness
, 2009
Hepatotoxicity and Gastrointestil Intolerance When Healthy Volunteers Taking Rifampin Add Twice
, 2009
Safety and Efficacy of Enfuvirtide in Combition with Daruvir
, 2008
Evaluation of high-protein supplementation in weight
, 2008
Virologic Response to Lopivir-Ritovir
, 2008
Initiatives for developing and comparing genotype interpretation systems
, 2008
Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
, 2008
Effect of concomitantly administered rifampin on the pharmacokinetics
, 2007
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor
, 2007
A randomized, partially blinded phase 2 trial of antiretroviral therapy
, 2006
N88D facilitates the co
, 2006
Incorporating drug-resistance measurements into the clinical magement of HIV-1 infection
, 2006
The study of fat redistribution and metabolic change in HIV infection (FRAM): Methods, design
, 2006
The effect of diagnosis with HIV infection on health-related quality of life
, 2006
Case files from Stanford University Medical Center
, 2006
Pharmacokinetic interactions between indivir plus ritovir and calcium channel blockers
, 2005
HIV-1 protease and reverse-transcriptase mutations
, 2005
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
, 2005
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation
, 2005
Detection of minority populations of HIV
, 2005
Prevalence of antiretroviral drug resistance in the HIV-1
, 2004
Clinically validated genotype alysis: guiding principles and statistical concerns
, 2004
High levels of adherence do not prevent accumulation of HIV drug resistance mutations
, 2003
Lack of detectable human immunodeficiency virus type 1 superinfection during 1072 person
, 2003
Extended spectrum of HIV
, 2003
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease
, 2003
Virtual inhibitory quotient predicts response to ritovir boosting of indivir
, 2002
Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to
, 2002
Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage
, 2002
Characterization of the HIV
, 2001
HIV drug resistance testing: an update for the clinician.
, 2001
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy
, 2001
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS
, 2001
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment
, 2001
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease
, 2001
Highly active antiretroviral therapy results in HIV type 1 suppression in lymph nodes
, 2000
Adherence to isoniazid prophylaxis in the homeless - A randomized controlled trial
, 2000
Adherence to protease inhibitors, HIV-1 viral load
, 2000
The relation between baseline HIV drug resistance and response to antiretroviral therapy
, 2000
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients
, 2000
HIV-1 genotypic resistance patterns predict response to saquivir
, 1999
Invasive fungal sinusitis due to Scedosporium apiospermum in a patient with AIDS
, 1999
Clinical resistance patterns
, 1999
Association between time homeless and perceived health status among the homeless in San Francisco
, 1997
PREVALENCE OF MEASLES ANTIBODIES IN ADULTS WITH HIV-INFECTION
, 1992
What is Dr. Zolopa's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Zolopa's National Provider Identifier (NPI) number is 1447264130.
What common questions do patients ask about Dr. Zolopa?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Zolopa
What is Dr. Andrew Zolopa's specialty?
Dr. Zolopa is a Infectious Disease Specialist near Stanford, CA.
What does an Infectious Disease Specialist do?
An internist who deals with infectious diseases of all types and in all organ systems. Conditions requiring selective use of antibiotics call for this special skill. This physician often diagnoses and treats AIDS patients and patients with fevers which have not been explained. Infectious disease specialists may also have expertise in preventive medicine and travel medicine.
Is this Dr. Andrew Zolopa affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Zolopa is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see an Infectious Disease Specialist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see an Infectious Disease Specialist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Andrew Zolopa accepting new patients in Stanford, CA?
Yes, Dr. Andrew Zolopa is accepting new patients at this time.
Does Dr. Andrew Zolopa offer online booking?
Please contact Dr. Zolopa's office at (208) 089-1800 for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Andrew Zolopa?
Please contact Dr. Zolopa's office at (208) 089-1800 for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Andrew Zolopa have?
Dr. Andrew Zolopa is certified by the American Board of Internal Medicine.
Other Infectious Disease Specialist Near Stanford, CA
Infectious Disease Specialist
Accepting patientsInfectious Disease Specialist
Accepting patients
Infectious Disease Specialist
Accepting patients